Elanco: acquires Kindred Biosciences

(CercleFinance.com) - Elanco Animal Health has announced an agreement to acquire Kindred Biosciences at a price of 9.
25 dollars per share, meaning a cash consideration of approximately 440 million dollars, representing a 52% premium above its average price over the past 30 days.

The veterinary drug company says that this deal brings three potential development-stage blockbusters, rounds out its existing pipeline and increases its monoclonal antibody R&D capabilities.

This biopharma company, which is focused on the development of novel therapies for pets based on validated human targets, should in particular strengthen Elanco's presence in the fast-growing dermatology segment.


Copyright (c) 2021 CercleFinance.com. All rights reserved.